Medicare AdvantageCoverageMedium impact
MA08.192, Belantamab mafodotin-blmf (Blenrep)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Apr 20, 2026
We identified it
Jun 19, 2026
Summary
This is a new Medicare Advantage pharmacy policy (MA08.192) establishing coverage and billing guidelines for belantamab mafodotin-blmf (Blenrep), a BCMA-directed cytotoxic immunoconjugate used in oncology. The billing team must implement this policy immediately to ensure proper claim processing for this newly covered drug effective April 20, 2026.
Action Required
By April 20, 2026: Pharmacy billing team must review the complete policy text at the source URL to identify specific HCPCS codes for belantamab mafodotin-blmf (likely J-codes for drug administration). Update billing software and pharmacy systems to recognize this drug as covered under MA08.192. Coordinate with oncology providers and pharmacy to ensure claims are submitted with appropriate diagnosis codes (C90.1x for multiple myeloma). Verify prior authorization requirements if specified in full policy. Train billing staff on any documentation or coding requirements. Failure to properly code and submit claims may result in denials or payment delays.